Definium Therapeutics (NASDAQ:DFTX) Raised to Strong-Buy at Wolfe Research

Definium Therapeutics (NASDAQ:DFTX) was upgraded by Wolfe Research to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

Other equities analysts have also recently issued reports about the stock. Royal Bank Of Canada upped their price objective on shares of Definium Therapeutics from $20.00 to $36.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Chardan Capital upgraded shares of Definium Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Thursday, January 22nd. Robert W. Baird set a $37.00 price objective on Definium Therapeutics in a research report on Thursday, January 29th. Finally, Canaccord Genuity Group upped their target price on Definium Therapeutics from $16.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Definium Therapeutics has a consensus rating of “Buy” and an average price target of $34.20.

Definium Therapeutics Stock Up 2.9%

Shares of NASDAQ DFTX opened at $17.45 on Monday. The company has a market cap of $1.72 billion, a price-to-earnings ratio of -8.55 and a beta of 2.57. The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31. Definium Therapeutics has a 12 month low of $4.70 and a 12 month high of $18.70. The stock has a 50-day moving average price of $15.36 and a two-hundred day moving average price of $12.69.

Insider Activity

In other news, insider Daniel Karlin sold 5,600 shares of the stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $73,640.00. Following the completion of the sale, the insider owned 425,025 shares of the company’s stock, valued at approximately $5,589,078.75. This represents a 1.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Robert Barrow sold 25,791 shares of Definium Therapeutics stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $339,151.65. Following the completion of the transaction, the chief executive officer directly owned 778,477 shares in the company, valued at approximately $10,236,972.55. This represents a 3.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 42,667 shares of company stock valued at $561,071. Company insiders own 2.26% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

A number of institutional investors have recently modified their holdings of the company. Royal Bank of Canada increased its position in shares of Definium Therapeutics by 10.4% during the first quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock worth $382,000 after buying an additional 6,148 shares during the period. CWM LLC grew its holdings in Definium Therapeutics by 67.4% during the 2nd quarter. CWM LLC now owns 4,459 shares of the company’s stock worth $29,000 after acquiring an additional 1,796 shares during the period. Teacher Retirement System of Texas grew its holdings in Definium Therapeutics by 9.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company’s stock worth $106,000 after acquiring an additional 1,400 shares during the period. Geode Capital Management LLC raised its position in shares of Definium Therapeutics by 4.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock worth $11,252,000 after acquiring an additional 66,663 shares in the last quarter. Finally, Creative Planning lifted its stake in shares of Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after purchasing an additional 1,655 shares during the period. 27.91% of the stock is owned by institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.